ArticleOncotarget2017

A phase I trial of NK-92 cells for refractory hematological malignancies relapsing after autologous hematopoietic cell transplantation shows safety and evidence of efficacy.

Brent A Williams et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.